Mammography

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Retrieved on: 
Tuesday, April 9, 2024
Health, Culture, EQUIP, Algorithm, Radiology, Partnership, Risk, ICAD, Physician, Patient, ACR, Accreditation, Mammography, Deep learning, GPT, DBT, Breast cancer, Safety, Machine learning, Breast, Medical imaging

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation

Key Points: 
  • Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation
    NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc .
  • (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc ., a global leader in operational AI solutions for breast cancer screening.
  • The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman’s breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk.
  • IntelliMammo® densityAI™ breast density has been clinically validated to have a strong association with breast cancer risk, providing a practical automated method for risk stratification.vi

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

Retrieved on: 
Wednesday, April 3, 2024
Health equity, Partnership, ICAD, Education, Patient, Global health, Mammography, Cancer, SBI, Breast cancer, Medical imaging

(NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International .

Key Points: 
  • (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International .
  • RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography AI-based decision support in LMICs, starting with an implementation in Guyana using iCAD’s ProFound Detection.
  • iCAD and RAD-AID aim to begin in Guyana where implementation of iCAD’s ProFound AI Detection Solution, coupled with RAD-AID’s educational and capacity-building initiatives, aims to increase, and improve breast cancer detection for patients in need.
  • “Our deployment of ProFound AI Detection in Guyana represents a significant step forward in the fight against breast cancer in low-resource settings.

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

Retrieved on: 
Tuesday, April 2, 2024
Cloud, Google Cloud, 2D, Software as a service, Partnership, ICAD, Patient, Software, 3D, Radiology, Cancer, AI, Mammography, Workflow, Graphics processing unit, PACS, System, Privacy, Triangle, Medical imaging

NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud.

Key Points: 
  • NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud.
  • The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Breast Health Suite of AI solutions.
  • “With the commercial launch of ProFound Cloud, iCAD is enabling interoperability and access to Breast AI Solutions at enterprise scale, revolutionizing global access to cutting-edge AI solutions in breast health,” said Dana Brown, president, and CEO of iCAD.
  • ProFound Cloud also manages ProFound Risk and Density assessment results, radiology and pathology reports and detection results, while ensuring seamless access to critical diagnostic information.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Istanbul University, Marmara University, Tekirdağ Namık Kemal University, Research, Mammography, Cancer, AI, Woman, MMG, Breast cancer, Workload, Therapy, ESR, Medical imaging

SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists' workload while enhancing cancer detection rates.

Key Points: 
  • This comprehensive study encompassed over 22,621 mammograms from 8,825 women over a decade.
  • Utilizing Lunit INSIGHT MMG, Lunit's AI-powered solution for breast cancer detection, the research aimed to assess its proficiency in early cancer detection within a breast cancer screening program.
  • This indicates a substantial step forward in improving the efficiency of breast cancer screening programs, potentially enabling broader screening coverage and reducing the burden on healthcare systems.
  • The study further revealed that the AI system identified 51.72% of interval cancers, and 50% of missed cancers.

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Retrieved on: 
Tuesday, March 19, 2024
2D, Radiology, ICAD, 3D, Mammography, Cancer, Medical imaging

“We're excited to introduce advanced workstation features for our flagship solution, ProFound Detection, aimed at further improving and facilitating radiologists' interpretation of mammograms within their workstation,” said Dana Brown, President and CEO of iCAD.

Key Points: 
  • “We're excited to introduce advanced workstation features for our flagship solution, ProFound Detection, aimed at further improving and facilitating radiologists' interpretation of mammograms within their workstation,” said Dana Brown, President and CEO of iCAD.
  • This refinement ensures that radiologists can interpret the most critical information thereby streamlining the diagnostic process for more efficient decision-making.
  • “From the inception of iCAD’s 2D Detection in 2002, to the launch of 3D Detection V1.0 in 2016, followed by 3D V2.0 Detection in 2018, and V3.0 Detection in 2021, each version has pushed the boundaries of cancer detection solutions.
  • Now, in 2024, the release of the V3 Detection Service Pack marks another milestone, representing a commitment to ongoing enhancement and ensuring that ProFound Detection remains at the forefront of early cancer detection solutions.”

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Growth, Ki-67, Neoadjuvant therapy, Mammography, Cancer, Expanded access, Woman, Neoplasm, Therapy, Breast cancer, CYP2D6, Safety, Axis, Osteoporosis, Hot, Recurrence, Tamoxifen, FDA, Enzyme inhibitor, PR, Pharmaceutical industry

Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Key Points: 
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • Over five years of adjuvant treatment, her daily (Z)-endoxifen treatment has been well tolerated, and there were no vasomotor symptoms commonly associated with standard of care adjuvant pharmaceuticals.
  • She remains cancer-free today and we are grateful to have been able to help her with a difficult treatment problem.”
    Diagnosis.
  • Under the FDA Expanded Access IND program, the use of Atossa's proprietary (Z)-endoxifen is restricted to this patient only.

NextGen Healthcare Chosen by United Medical Centers to Support Integrated Care Delivery in Communities at United States-Mexico Border

Retrieved on: 
Monday, March 18, 2024
Data Management, Health, Technology, Practice Management, Health Technology, Software, General Health, Internal medicine, FQHC, Documentation, Mammography, Cardiology, Patient, Interface (computing), Thought, UMC, EHR, NextGen Healthcare, Podiatry, Luma

Driven by its mission of delivering high-quality, affordable healthcare across highly bilingual communities on the United States-Mexico border, United Medical Centers (UMC Health) has chosen NextGen Healthcare as its healthcare technology partner.

Key Points: 
  • Driven by its mission of delivering high-quality, affordable healthcare across highly bilingual communities on the United States-Mexico border, United Medical Centers (UMC Health) has chosen NextGen Healthcare as its healthcare technology partner.
  • NextGen® Enterprise electronic health record (EHR) and NextGen® Enterprise practice management (PM) will boost integration across specialties and sites of care as the organization grows and adds new services.
  • With nine locations, the center offers family medicine, internal medicine, pediatric care, obstetrics-gynecology, cardiology, podiatry, dental and pharmacy services.
  • At NextGen Healthcare, we remain committed to supporting FQHCs who are helping their communities thrive.”
    To learn more about NextGen Healthcare, visit nextgen.com .

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

Retrieved on: 
Thursday, March 14, 2024
Technology, Hospitals, Health Technology, Other Health, Radiology, Health, Pharmaceutical, Data Management, Artificial Intelligence, Diagnosis, Deep learning, PET/CT, Head, Experiential learning, Algorithm, Longevity, MRI, X-ray, HHC, Anesthesia, OEC, Patient, Artificial intelligence, Acquisition, Mammography, Software, Critical care, GE HealthCare, Artifact, Multimedia, Nuclear medicine

The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.

Key Points: 
  • The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.
  • The collaboration will increase patients’ access to GE HealthCare’s most current imaging technology, and may provide shorter scan times, reduced waiting times for care, and enable clinicians to have greater accuracy in diagnostic assessments.
  • The agreement also includes GE HealthCare patient monitoring, anesthesia, maternal infant care and diagnostic cardiology technologies.
  • GE HealthCare and Hartford HealthCare will also execute build-in-place upgrades with some existing MRI, CT, PET/CT, and X-rays to refresh older systems with fewer construction costs and while minimizing waste, equipment downtime, and disruption to patient care.

iSono Health Applauded by Frost & Sullivan for Ensuring Patient Comfort and Safety and Providing Quality Imaging and Diagnosis with its iSono Health ATUSA

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, ROI, Frost, Consultant, Health, Patient, SAN, Tissue, Hospital, Health care, Acquisition, Mammography, Overalls, Google Images, ABUS, HCP, FDA, Medical imaging

SAN ANTONIO, April 3, 2024 /PRNewswire/ -- Recently, Frost & Sullivan assessed the breast ultrasound industry and, based on its findings, recognizes iSono Health with the 2023 United States New Product Innovation Award. The company is carving a new category for the automated breast ultrasound (ABUS) market. The iSono Health ABUS ATUSA is approved by the US Food and Drug Administration (FDA) and is the world's first automated, portable, and wearable three-dimensional (3D) breast ultrasound. The scanner attaches to a unique wearable accessory with intuitive software that automates image acquisition and analysis and does not require trained breast ultrasound technicians.

Key Points: 
  • iSono Health AI ABUS ATUSA enables precise and prompt screening, eliminates delays and the need for trained technicians, provides cost-effective imaging, and improves patient outcomes significantly.
  • The iSono Health ABUS ATUSA is approved by the US Food and Drug Administration (FDA) and is the world's first automated, portable, and wearable three-dimensional (3D) breast ultrasound.
  • Poornima Srinivasan, Consultant at Frost & Sullivan, observed, "iSono Health is revolutionizing the ABUS diagnostic imaging market with its wearable accessories and 3D image acquisition.
  • With its strong overall performance, iSono Health earned Frost & Sullivan's 2023 United States New Product Innovation Award in the breast ultrasound industry.